Effects of Using Generic Drugs on Medicare's Prescription Drug Spending
DIANE Publishing, 2011 - 36 pages
This is a print on demand edition of a hard to find publication. Contents:(1) Overview of the Medicare Prescription Drug Benefit Program: Design of the Medicare Prescription Drug Benefit; Distribution of Spending in Medicare Part D; The Role of Private Plans in Medicare Part D; (2) Generic Drugs in Medicare Part D: Generic Substitution; Therapeutic Substitution; Comparing Potential Savings from Generic and Therapeutic Substitution; (3) Implications of Future Developments: First-Time Generic Entry; New Brand-Name Drugs; Biologics. (4) Appendix: Description of Data Used in This Analysis. Charts and tables.
What people are saying - Write a review
We haven't found any reviews in the usual places.
$4 billion 2010 Annual Report actuarial average price behalf of enrollees biologics biosimilars Board of Trustees Budget Office based CBO estimates CBO’s Centers for Medicare chemically equivalent cholesterol coinsurance Congressional Budget Office copayments coverage gap D program payments drug sold estimates of savings first-time generic entry formularies hospice care incentives Insurance and Federal Medicaid Services Medical Insurance Trust Medicare and Medicaid Medicare Board Medicare Part D Medicare Payment Medicare Prescription Drug million prescriptions multiple-source brand-name drugs name drugs payments to plans percent of total plan’s plans and pharmacies Potential Additional Savings potential savings premiums prescription drug benefit prescription drug costs Prescription Drug Event prescription drug spending prescriptions filled private plans program payments Proton pump inhibitors rebates reduced retiree drug subsidy savings from therapeutic Savings per Prescription seven classes single-source brand-name drugs standard benefit Statins substitu therapeutic class therapeutic substitution total payments total prescription drug Trust Funds August